DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have received a consensus rating of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $48.50.

DBVT has been the topic of several recent analyst reports. Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. Guggenheim restated a “buy” rating and issued a $51.00 price target on shares of DBV Technologies in a research note on Monday, May 4th. Finally, Citizens Jmp upped their price objective on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a report on Friday, May 1st.

Hedge Funds Weigh In On DBV Technologies

A number of institutional investors and hedge funds have recently made changes to their positions in DBVT. Allworth Financial LP purchased a new position in shares of DBV Technologies in the 4th quarter valued at about $32,000. Royal Bank of Canada purchased a new stake in DBV Technologies during the fourth quarter worth about $34,000. GAMMA Investing LLC boosted its holdings in DBV Technologies by 38.4% during the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after buying an additional 744 shares in the last quarter. New York State Common Retirement Fund acquired a new position in DBV Technologies during the third quarter worth about $34,000. Finally, Truvestments Capital LLC increased its holdings in DBV Technologies by 71.3% in the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after buying an additional 1,620 shares in the last quarter. 71.74% of the stock is owned by institutional investors and hedge funds.

DBV Technologies Stock Performance

DBVT stock opened at $15.53 on Friday. The stock has a market capitalization of $919.53 million, a PE ratio of -3.48 and a beta of -0.99. The company has a fifty day moving average of $19.09 and a 200-day moving average of $19.78. DBV Technologies has a one year low of $8.50 and a one year high of $26.18.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). The firm had revenue of $0.90 million for the quarter, compared to analyst estimates of $1.11 million. DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%. Equities analysts forecast that DBV Technologies will post -0.47 earnings per share for the current fiscal year.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.